Recent results have revealed that the p53 tumor suppressor protein possesses a direct transcription-independent apoptotic activity. During apoptosis induced by genotoxic stress, a small fraction of p53 is targeted to mitochondria where it initiates apoptosis by causing mitochondrial dysfunction. In adenovirus-infected cells, the expression of E1A protein enhances the accumulation of p53 during early phases of infection and during late times after infection, it is targeted for degradation by the combined action of E1B-55K and E4-orf6 proteins. The functional significance of E1A-mediated accumulation of p53 during early phases of viral replication is not known. Our studies with isogenic epithelial cell lines that differ only on the status of p53 indicate that Ad infection induces apoptosis by p53-dependent and -independent pathways and both pathways are suppressed by E1B-19K. We show that during early phase of Ad infection, a fraction of p53 is targeted to the mitochondria. In virus infected cells, a large fraction of the viral antiapoptosis protein E1B-19K is also localized in mitochondria during early and late phases of infection. Coimmunoprecipitation analysis has revealed that p53 and E1B-19K form a complex in mitochondria. The interaction of 19K involves two noncontiguous regions located around amino-acid residues 14-15 and 123-124. On p53, the mutations within the DNA-binding domain reduce interaction with E1B-19K. Our studies also suggest that 19K may additionally complex with the multidomain mitochondrial proapoptotic protein BAK, thereby reducing the level of p53 interaction with BAK. We suggest that p53-induced apoptosis may be important for efficient cell lysis and viral spread and that E1B-19K may neutralize the apoptotic activity of p53 at multiple levels.
Introduction
The tumor suppressor protein p53 plays an important role in preventing oncogenesis and the p53 function is lost or compromised in most human cancers (Vogelstein et al., 2000; Vousden and Lu, 2002; Benard et al., 2003) . The p53 protein responds to oncogenic and genotoxic stress either by mediating growth arrest or by inducing apoptotic cell death, depending on the cell type or the cellular growth environment (reviewed in Vogelstein et al., 2000; Balint and Vousden, 2001) . The p53 protein is primarily a transcriptional regulator and can induce apoptosis by transcriptional activation of proapoptotic genes such as Noxa (Oda et al., 2000) , Puma (Nakano and Vousden, 2001; Yu et al., 2001 Yu et al., , 2003 and Bax (Miyashita and Reed, 1995) and/or by transcriptional repression of antiapoptotic genes such as Bcl-2 (Wu et al., 2001) , Iap (Hoffman et al., 2002; Mirza et al., 2002) . A number of similar reports have also established a critical link between the transcriptional regulatory activity of p53 and apoptosis (reviewed in Vousden and Lu, 2002) . However, several other studies have suggested that p53 can induce apoptosis independent of its effects on transcription (Caelles et al., 1994; Haupt et al., 1995; Chen et al., 1996b; Kokontis et al., 2001) . For example, mutants of p53 deficient in transcriptional activity or deficient in nuclear localization are not severely retarded in their apoptotic potential . Additionally, p53 has also been reported to promote apoptosis even in the presence of transcriptional inhibitors . These results are consistent with the interpretation that the p53 protein has a direct apoptotic activity, independent of its transcriptional regulatory activity. This activity of p53 has been ascribed to a fraction of p53 that is targeted to mitochondria in response to apoptotic stress (Marchenko et al., 2000; Dumont et al., 2003; Mihara et al., 2003; .
Owing to the multiple roles of p53 as a 'central molecular switchboard' (Perfettini et al., 2004) , its activity is highly regulated by divergent pathwaysthrough transcription (Webster and Perkins, 1999) , translation (Fu et al., 1996) , post-translational modifications (Xu, 2003) , cellular compartmentalization (Liang and Clarke, 2001) as well as association with a complex protein network, with MDM2 being the primary regulator of p53 stability and activity . Since the life cycles of small DNA viruses such as polyomaviruses, papillomaviruses and adenoviruses require proliferation of normally quiescent host cells, they have also evolved strategies to overcome growth suppressive and apoptotic activities of p53 (reviewed in Moran, 1993; Beck et al., 1998; Collot-Teixeira et al., 2004) . For example, the large T antigen of SV40 tightly binds to p53, stabilizes and sequesters it from normal cellular targets (Lane and Crawford, 1979; Linzer and Levine, 1979) while the E6 oncoprotein of human papillomaviruses HPV-16 and HPV-18 target p53 for proteolysis (Werness et al., 1990; Crook et al., 1991) . In cells infected with human adenoviruses, the p53 protein is stabilized as a result of expression of the E1A proteins during early stages of infection (Debbas and White, 1993; Lowe and Ruley, 1993; Grand et al., 1994) . At later stages of infection, the normal function of p53 is prevented by two viral proteins, E1B-55K (Sarnow et al., 1982) and E4-orf6 (Dobner et al., 1996) , that complex with p53. The E1B-55K protein binds to the N-terminal transactivation domain of p53 (Yew and Berk, 1992; Yew et al., 1994; Teodoro and Branton, 1997) while E4-orf6 binds to the C-terminal region (Dobner et al., 1996; Querido et al., 2001a) and alter the transcriptional activity of p53. The combined actions of these two proteins target p53 to proteolysis (Moore et al., 1996; Steegenga et al., 1998; Querido et al., 2001a, b; Harada et al., 2002) . Although elevated levels of p53 are observed in Ad-infected cells until late stages of infection, the functional significance of p53 accumulation during early stages of viral replication is not clear. It is generally assumed that p53 negatively regulates adenovirus replication and this effect is relieved by E1B-55K and E4-orf6. The observation that certain mutants of E1B-55K defective in binding to and downregulation of p53 have been shown to replicate efficiently in the presence of large amounts of phenotypically wt p53 (in a cell line that expresses a ts mutant of p53) (Shen et al., 2001) suggests that other viral gene products may also modulate the activity of p53 during viral infection.
Adenovirus E1B-19K protein plays a dominant role in amelioration of apoptosis during viral infection and facilitates efficient viral replication. The 19K protein is a viral homolog of the cellular antiapoptosis protein BCL-2, since BCL-2 can efficiently substitute for E1B-19K during viral replication Chiou et al., 1994; Subramanian et al., 1995b) , they both interact with a common set of cellular proapoptotic proteins (Boyd et al., 1994 (Boyd et al., , 1995 Farrow et al., 1995; Chen et al., 1996a; Han et al., 1996a, b) and share limited aminoacid sequence homology over certain conserved domains (Chiou et al., 1994; Subramanian et al., 1995a) . In addition to suppressing apoptosis during viral infection, expression of 19K can efficiently overcome apoptosis mediated by ectopic overexpression of p53 (Debbas and White, 1993) and by stimuli such as DNA-damaging agents that cause activation of p53 Tarodi et al., 1993) . In light of the recently demonstrated direct apoptotic activity of mitochondrially targeted p53, it is of interest to determine if p53 is targeted to mitochondria in Ad infected cells and if E1B-19K can regulate the activity of p53 in mitochondria.
Results

p53-dependent and -independent apoptosis in Ad-infected cells
It is well documented that p53 is critically involved in apoptotic cell death induced by various types of genotoxic stress stimuli. Although a number of studies have attempted to investigate the role of p53 in adenovirus induced apoptosis and in Ad replication, these issues continue remain murky. Part of the difficulty in directly addressing the role of p53 during productive viral life cycle has been the use of various human cancer cell lines that either have wt p53 or mutant p53. Such studies have suffered due to the inherent heterogeneity among the different cell lines. To investigate whether p53 plays any potential role in Ad-induced apoptosis, we used two genetically matched cell lines that differ only on the p53 status. The colon cancer cell line HCT116 expresses wt p53 (p53 þ / þ ) and an isogenic derivate of this cell line (HCT116 p53
) is null for p53 due to disruption of both alleles of p53 by gene targeting (Bunz et al., 1999) . HCT116 cells are responsive to various apoptotic stresses (Theodorakis et al., 2002) , including Ad infection and are widely used to study the apoptosis pathways. Moreover, HCT116 cells have a functional wild-type p53-dependent signaling network (MahyarRoemer et al., 2004) . To determine the role of p53 in Ad-induced apoptosis, HCT116 p53 þ / þ and p53
À/À cells were infected with Ad2 wt or the apoptogenic mutant dl250 (defective in E1B-19K) at 50 PFU/cell and the cytopathic effect and cell viability were determined ( Figure 1a ). The mutant dl250 induced massive apoptosis causing about 40% loss in cell viability within 48 h after infection and 70% within 72 h after infection in p53-expressing cells. The mutant dl250 also induced significant level of cell death in p53-null cells. However, the extent of apoptosis was lower than that in p53-expressing cells. In contrast to dl250, Ad2 wt induced only low level of cell death in both cell lines. The role of p53 in virus-induced apoptosis was also determined by analysis of fragmentation of the cellular DNA ( Figure 1b ). As expected, infection with dl250 induced extensive DNA fragmentation (compared to infection with Ad2 wt) in both cell lines. The extent of DNA fragmentation was consistently lower in p53 À/À cells. Similar results were also obtained in cells infected with a different Ad5 19K mutant, dl111 compared to cells infected with Ad5 dl309 (phenotypic wt) (not shown). The relationship between p53 expression and Ad-induced apoptosis was also assessed using a statistical approach (Collett, 2003) (Figure 1c) . We estimated the hazard functions for Ad infection in p53 þ / þ and p53 À/À cells. The cumulative risk of death in HCT116 p53 þ / þ and p53 À/À cells infected with Ad2 wt was similar and remained relatively low. As expected, infection with dl250 significantly increased the risk of death (compared to Ad2 wt) in both cell types. In addition, comparative analysis of the hazard function curves for p53
þ / þ and p53 À/À cells infected with dl250 revealed that in p53-expressing cells, the dl250-dependent risk of death was significantly higher as the risk of death in p53 null cells over time.
Additionally, we also used an assay based on the viral spread to determine the role of p53-mediated apoptosis in productive viral life cycle. It has been previously shown that p53 plays an important role in Ad spread through virus-mediated cytopathic effect and cell lysis (Hall et al., 1998) . To investigate the effect of p53-mediated apoptosis in viral spread, we determined the viral titers after multiple cycles of viral replication (144 h after infection) in p53 þ / þ and p53 À/À cells that were infected with Ad2 wt or dl250 at low multiplicities of infection (0.1 PFU/cell). The titer of dl250 in p53 þ / þ cells was substantially higher than that of Ad2 wt (Figure 1d ). The titer of dl250 was also higher in p53 À/À cells compared to Ad2 wt, although at reduced levels than in p53 þ / þ cells. These results suggest that in cells infected with dl250, apoptosis occurs through both p53-dependent and -independent mechanisms and that apoptosis may facilitate for efficient viral spread.
Accumulation of p53 and viral early proteins during Ad infection
To determine the relative levels of p53 and the levels of viral early proteins (that regulate the activities of p53) during the Ad2 infection cycle, HCT116 p53
þ / þ cells were infected with Ad2 wt or dl250. At various time after infection cell extracts were collected, subjected to SDS-PAGE and immunoblot analysis (Figure 2 ). These results revealed that the levels of p53 increased 6 h after infection in cells infected with Ad2 wt or dl250 (Figure 2a ). The level of p53 accumulation declined at 24 h after virus infection while the level remained unchanged in mock-infected cells. We have also consistently observed a slightly elevated levels of p53 in dl250-infected cells at late times compared to wt infected cells (compare Ad2 wt and dl250 lanes at 36 h PI). The analysis of viral proteins revealed that E1B-19K was clearly present by 6 h postinfection and the levels increased substantially at late times after infection (Figure 2b ). The expression of E1B-55K protein was also detectable at 6 h after infection and was maximal around 24 h after infection. Expression of the E4 proteins, E4-orf6 and orf6/7 was also detectable as early as 6 h after infection and the levels increased slightly between 12 and 24 h postinfection. These results are consistent with the observation by Grand et al. (1994) and show that downregulation of p53 by viral E1B-55K and E4-orf6 proteins may be a late event (i.e. 24 h after infection). It should be noted that during the periods of infection between 6 and 24 h when increased levels of p53 was observed, cells also contained high level of E1B-19K. Cells infected with dl250 also exhibited similar patterns of E1B-55K, E4-orf6 and E4-orf6/7 (not shown). Our results suggest the possibility that E1B-19K may antagonize the apoptotic activity of p53 during early phases of infection.
Translocation of p53 to mitochondria during Ad infection
Previous reports by Moll and co-workers have shown that a fraction of p53 translocates to the mitochondria after treatment of cells with different agents that cause genotoxic stress and such localization contributes to the direct apoptotic activity of p53 (Marchenko et al., 2000; Mihara et al., 2003) . We asked whether p53 is also targeted to mitochondria during Ad infection. To address this question, we carried out an immunoblot analysis of subcellular fractions prepared from mockinfected or virus-infected cells. The relative purity of the mitochondrial and nuclear fractions were determined by immunoblot analysis of markers associated with these fractions (Figure 3a ). The heavy membrane fraction Mitochondrial interaction between p53 and E1B-19K E Lomonosova et al (mitochondrial) was highly enriched for COX IV (a strictly mitochondrial enzyme) and did not contain detectable levels of PCNA (a nuclear marker). The cytosolic/light membrane fraction and the nuclear fraction also did not contain detectable levels of COX IV. Similar results were also obtained with subcellular fractions prepared from Ad-infected cells (data not shown). The subcellular fractions from mock-infected and Ad-infected cells were then analysed for the presence of p53 (Figure 3a) . In cells infected with Ad2 wt or dl250 a fraction of p53 was found to be rapidly localized in the mitochondrial fraction (i.e. as early as 6 h postinfection). The mitochondrially localized p53 was readily detectable until 12 h postinfection and then declined. The overall pattern of mitochondrial localization of p53 paralleled the pattern of accumulation of total p53 during Ad infection (Figures 2a and 3a) . The time course of mitochondrial p53 accumulation paralleled the cytosolic and total p53 levels ( Figure 2a ) during Ad infection. Thus, our results suggest that a fraction of p53 is targeted to mitochondria during early phases of Ad infection.
Localization of p53 and E1B-19K in mitochondria
Next, we asked whether any Ad proteins are also localized in mitochondria to modulate the apoptogenic activity of mitochondrial p53. Due to the established antiapoptotic activity of E1B-19K, it was of interest to determine if E1B-19K also localizes in mitochondrial fractions during p53 accumulation. Western blot analysis of the subcellular fractions prepared at different times after infection with Ad2 wt showed abundant presence of 19K in mitochondrial and nuclear fractions ( Figure 3b ). The 19K protein was present in mitochondrial fraction as early as 6 h after infection. The presence of E1B-19K in the nuclear fraction may correspond to the 19K protein that might be localized on the nuclear membrane (White et al., 1984) . Additionally, we also examined the presence of E1B-55K and E4 proteins in these fractions. The E1B-55K and E4-orf6 proteins were detected in nuclear and cytosolic fractions with the kinetic similar of total proteins expression (early) during Ad infection (Figure 2b) . Thus, our results show that E1B-19K rapidly accumulates in the mitochondria after Ad infection concomitant with p53 localization in mitochondria.
Interaction of E1B-19K with p53
Since E1B-19K prevents p53 dependent apoptosis and also cofractionates with p53 in mitochondria, we reasoned that E1B-19K might interact with p53 to antagonize the apoptotic activity of p53. To determine if E1B-19K interacts with p53, we first used a transient transfection and coimmunoprecipitation analysis.
HCT116 p53
À/À cells were cotransfected with plasmid vectors that express p53 or 19K. The proteins were immunoprecipitated with the agarose conjugate of antip53 monoclonal antibody (DO-1) and the immunoprecipitates were subjected to a Western blot analysis using the 19K or p53 antibody (Figure 4a ). The immune complex precipitated with the p53 antibody contained significant amount of 19K. In a converse experiment, immunoprecipitation with the 19K antibody and probing the Western blot with p53 antibody, revealed significant amount of p53 (Figure 4b ). These results were also confirmed by using a rat monoclonal 19K antibody for immunoprecipitation (results not shown). Next, we determined if 19K associates with endogenous p53. For this purpose, we infected HCT116 p53 þ / þ cells with Ad2 wt or dl250, and treated the infected cells with AraC to prevent transition to late stages of infection. The expression of early viral proteins was ascertained by analysis of E1B-55K and E4-orf6 (not shown). Coimmunoprecipitation with the DO-1 antibody (p53) revealed the presence of E1B-19K in the complex with p53 ( Figure 4c ). To further characterize interaction of E1B-19K with p53, we infected HCT 116 p53 þ / þ cells with different Ad5 E1B mutants 
Cell extracts were subjected to immunoprecipitation with the DO-I antibody followed by Western blot analysis with p53 and 19K antibodies. Again, E1B-19K was found to complex with p53 in cells infected with dl309 or dl110 (Figure 4d ). Together these observations reveal that E1B-19K associates with p53 in Ad infected cells even in the presence of E1B-55K and E4-orf6, and that E1B-19K interaction with p53 is independent of interaction with E1B-55K. Since E1B-19K and E1B-55K colocalize with p53 in different cellular compartments (Figure 3b ), they appear to target different pools of p53. While E1B-55K and E4-orf6 inactivate p53 in the cytosol and nuclei, E1B-19K may suppress mitochondrial apoptotic activity of p53 by specifically complexing with p53 in mitochondria. To address this issue directly, we prepared mitochondrial fraction from cells (HCT116 p53 þ / þ ) infected with Ad2 wt and carried out coimmunoprecipitation analysis (Figure 4e ). Again, E1B-19K was readily detectable in complex with p53 in the mitochondrial fraction. To further substantiate the interaction between p53 and 19K, we have also carried þ / þ cells were untreated, mock-infected or infected with different Ad5 mutants and at 24 h after infection, cell lysates were immunoprecipitated with agarose conjugates of the p53 antibody (DO-1) and the blots were probed for 19K. The p53 levels in wholecell lysates are shown. In lysates from cells infected with dl309, p53 was detectable when the film was overexposed. (e) Interaction of p53 and E1B-19K in mitochondria. The heavy membrane fraction of HCT116 p53 þ / þ cells prepared at 16 h after infection with Ad2 wt, immunoprecipitated with the p53 antibody and analysed by Western blotting. (f) In vitro binding of 19K and p53. GST pull-down assay was performed using full-length human recombinant p53 protein and GST and GST-19K fusion proteins. Protein complexes were analysed by SDS-PAGE and Western blotting. The levels of GST and GST-19K fusion proteins in the analysis were ascertained by staining with Sypro orange and the levels of p53 input were determined by Western blot analysis. The anti-p53 Ab DO-1 and the 19K antiserum were used to probe the Western blots in (a) through (f)
Mitochondrial interaction between p53 and E1B-19K E Lomonosova et al out an in vitro GST pull-down assay. GST or GST-19K fusion proteins were incubated with equal amounts of recombinant p53 protein and the protein complexes were analysed by Western blotting (Figure 4f ). These studies indicated association of significant amounts of p53 with GST-19K and not with GST. These results reinforce the results obtained from immunoprecipitation analysis.
Structural basis for E1B-19K and p53 interaction
We next asked the question through which regions p53 and 19K interact. E1B-19K is a functional homolog of BCL-2 and BCL-xL. However, the overall sequence similarity between these proteins is limited. It has been reported that the BCL-xL interacting surface on p53 involves its core DNA-binding region (Mihara et al., 2003; Petros et al., 2004) . We examined interaction of three different mutant p53, R173H, L194F and R273H with E1B-19K. These mutations are located within the DNA-binding domain of p53 and often arise in human tumors. Plasmid vectors expressing p53 wt or various mutants were cotransfected with the plasmid vector expressing E1B-19K in HCT116 p53
À/À cells. The proteins were immunoprecipitated with the p53 antibody and Western blots were probed with the 19K antibody (Figure 5a ). Among the mutants tested, mutants L194F and R273H interacted with 19K at reduced levels while mutant R175H was significantly defective for interaction. These studies suggest that E1B-19K may interact with the DNA-binding domain of p53, like BCL-xL.
The p53-binding region on BCL-xL was first deduced by model building (Mihara et al., 2003) and was confirmed by NMR spectroscopy (Petros et al., 2004) . This region consists of the carboxy-terminus of a1, the loop between a3 and a4, and the loop between a5 and a6 of Bcl-xL (Petros et al., 2004) . To identify the region of E1B-19K that mediate interaction with p53, we transfected plasmids expressing E1B-19K wt or different 19K mutants into HCT116p53 þ / þ cells, immunoprecipitated with the p53 antibody and probed the Western blots with the 19K antibody. Our results indicated that the 19K mutant E2A/A3S interacted with p53 as well as 19K wt, while mutants R14A/ N15S and W123A/R124S interacted very weakly (Figure 5b) . Interestingly, E2A/A3S mutant was reported to cooperate with E1A in transformation of BRK cells as well as 19K wt, whereas mutants R14A/ N15S and W123A/R124S were defective in E1A-cooperative transformation . Additionally, 19K wt and E2A/A3S mutant efficiently suppressed cisplatin-induced apoptosis but R14A/N15S and W123A/R124S mutants were defective to protect against cisplatin toxicity . It is generally accepted that cytotoxicity of cisplatin is mediated through induction of apoptosis and arrest of cell cycle resulting from its interaction with DNA, such as the formation of cisplatin-DNA adducts, which activates multiple signaling pathways, including those involving p53 (see Wang et al., 2004 for a recent review). Similarly, the E1A-cooperative transformation activity of E1B-19K has also been solely ascribed to the ability of 19K to suppress the p53-induced apoptosis (Debbas and White, 1993) . To determine the effect of 19K on p53-induced apoptosis more directly, we have used a colony rescue assay of a baby rat kidney (BRK) cell line that expresses a ts allele of p53 (Val135) (Michalovitz et al., 1990) . The BRK cells transformed with Ad E1A and the ts mutant of p53 undergo massive apoptosis (Debbas and White, 1993; Theodorakis et al., 1996) when p53 assumes wt conformation at 32.51C. One such BRK lines (Theodorakis et al., 1996) was transfected with plasmids that express wt 19K or various 19K mutants. The transfected cells were incubated at the nonpermissive temperature (38.51C) for 48 h and shifted to the permissive temperature (32.51C). At 48 h after incubation at the permissive temperature (which caused >90% cell death in untransfected cells), the surviving cells were rescued by shifting to 38.51C and allowed to form colonies. Quantification of the rescued cells indicated cells transfected with wt 19K or mutant E2A/A3S formed relatively higher number of colonies than the cells transfected with mutants R14A/N15S and W123A/R124S. These results closely parallel the pattern of interaction of 19K with p53 suggesting that these two activities of 19K are related.
Taken together, our studies suggest that the regions of E1B-19K located around residues 14-15 and 123-124 are essential for interaction with p53. Based on sequence alignment, it was proposed that residues 14-15 in E1B-19K protein might be located within a1 helix corresponding to the BH4 domain of different viral and cellular BCL-2 family antiapoptotic proteins while residues 123-124 might be located within the potential BH2 domain (a6 helix) (Cuconati and . Further analysis is clearly needed to define 19K sequences involved in complex formation with p53 in more detail.
Effect of E1B-19K on p53-BAK complex
To further extend our findings that E1B-19K targets mitochondrial p53 to prevent apoptosis, we coinfected HCT116 p53
À/À cells with an Ad vector expressing p53 and an Ad vector expressing either LacZ or a version of E1B-19K tagged with the Flag epitope. First, the effect on p53-mediated apoptotic response was determined on the basis of fragmentation of cellular DNA (Figure 6a ). In cells coinfected with Ad-p53 and Ad-LacZ there was extensive DNA fragmentation while in cells infected with Ad-p53 and Ad-19K, the extent of DNA fragmentation was significantly reduced. Western blot analysis of whole-cell extracts confirmed the expression of significant amounts of various proteins after infection of these vectors (Figure 6b ). To better understand the role of E1B-19K on modulating the activity of mitochondrial p53, we focused on an apoptosis promoting protein complex between p53 and BAK (Leu et al., 2004) . BAK (a multidomain proapoptotic protein) is an integral mitochondrial membrane protein and was shown to interact with p53 during apoptosis (Leu et al., 2004 ). Therefore, we tested if p53 also interacts with BAK in our experimental system. Analysis of the wholecell extracts by immunoprecipitation and Western blotting showed that BAK was complexed with p53 ( Figure 6c , results with the BAK antibody are shown in the figure) . Similar results were obtained with the p53 antibody (not shown). In these analyses we were unable to detect the association between p53 and another multidomain proapoptotic protein, BAX (data not shown). Other investigators have also observed no direct BAX interaction with p53, despite a reported requirement of BAX for the cell death activity of p53 (Chipuk et al., 2004) . Our data are consistent with those of Leu et al. (2004) , which suggests complex formation between mitochondrial p53 and BAK. Interestingly, E1B-19K also efficiently interacts with BAK (Degenhardt et al., 2000; Lomonosova et al., 2002) . Therefore, we sought to determine whether 19K could alter the BAKp53 complex. We coinfected cells with Ad-19KFlag or Ad-LacZ and Ad-p53, performed coimmunoprecipitation analysis with p53 or Flag antibodies and compared the amount of BAK in complexes with p53 and 19K in cells expressing a single target protein (p53 or 19K) or both target proteins (p53 and 19K). Coexpression of 19K-Flag and p53 resulted in a decrease in the level of p53 coprecipitated with BAK compared to cells that coexpressed p53 and LacZ (B35%). Similarly, the amount of BAK coimmunoprecipitating with 19K-Flag was less when 19K was coexpressed with p53 compared to the cells expressed 19KFlag and LacZ (B40%). Notably, 19K and BAK bind to p53 through the same region (Figure 5a ; Leu et al., 2004) . Our data are consistent with the interpretation that 19K may suppress p53-induced mitochondrial apoptosis by individually complexing with p53 and BAK and possibly by reducing the threshold levels of the p53-BAK complex in mitochondria.
Discussion
The role of p53 in Ad life cycle has been intensely studied. The initial interest on the role of p53 in Ad replication was stimulated by the observation that during early stages of Ad infection, there is an enhanced accumulation of p53 as a result of E1A expression (reviewed in Gallimore and Turnell, 2001 ). The E1A proteins influence the expression of p53 at multiple levels. E1A has been reported to stimulate transcription of the p53 gene through enhanced binding of the transcription factor E2F to the p53 promoter (Hale and Braithwaite, 1999) . The pronounced effect of E1A appears to be at the level of stabilization of p53 protein (Lowe and Ruley, 1993) . The ability of E1A to stabilize p53 appears to be linked to its interaction with the cellular proteins pRb and p300 (Chiou and White, 1997; Querido et al., 1997b) . The interaction of E1A with pRb appears to contribute to stabilization of p53 through E2F-dependent activation of p19 ARF and consequent downregulation of the ubiquitin ligase Mdm2 (de Stanchina et al., 1998) . Similarly, interaction of E1A with p300 also appears to inhibit an intrinsic ubiquitin ligase activity of p300 specific for p53 (Grossman et al., 2003) . E1A may also increase p53 levels via interaction with and inhibition of SUG1, a regulatory subunit of proteasome that are responsible for p53 degradation (Turnell et al., 2000) . Thus, the mechanism of E1A-mediated accumulation of p53 has come into focus. However, the functional consequence of E1A-induced accumulation of p53 during early phases of Ad infection remains obscure. It has been reported that ectopically overexpressed p53 is able to induce p21 expression in Ad-infected cells (Koch et al., 2001) . However, recently it has been shown that the endogenous p53 remains transcriptionally inactive in Ad-infected cells, independent of its interaction with E1B-55K and E4-orf6 (Hobom and Dobbelstein, 2004) . Interestingly, despite the lack of transcriptional activity, p53 accumulated during virus infection appears to increase the susceptibility of the infected cells for apoptosis (Hobom and Dobbelstein, 2004) . During late stages of productive virus infection, p53 is effectively disabled by E1B-55K and E4-orf6, which target p53 for proteosome-mediated degradation (Querido et al., 1997a (Querido et al., , 2001a Harada et al., 2002) . The protein complex consisting of E1B-55K, E4-orf6 and p53 is detected only 14-16 h after infection (Querido et al., 1997a; Harada et al., 2002) . Thus, Adinfected cells contain elevated levels of p53 during early phases of infection, possibly in a transcriptionally compromised apoptogenic form. We have detected mitochondrial localization of p53 as early as 6 h postinfection. Taking into account the published data from different laboratories on that transcription-independent induction of apoptosis by mitochondrial p53 (Dumont et al., 2003; Mihara et al., 2003; Chipuk et al., 2004) , we suggest that the fraction of p53 targeted to mitochondria may sensitize Ad infected cells for p53-depedent apoptosis. However, such an apoptotic response may be kept in check by the action of E1B-19K that also localize in mitochondria in significant amounts.
The mechanism by which p53 is targeted to mitochondria during Ad infection remains to be elucidated. A previous study has shown that p53 modified by poly-ubiquitination is targeted to mitochondria where it initiates apoptosis (Dumont et al., 2003) . In contrast, a different study using purified native form of p53 protein has been shown to permeabilize mitochondria and initiate apoptosis (Chipuk et al., 2004) . Further studies would be needed to determine if any Adinduced modification of p53 or an active mitochondrial import mechanism plays a role in targeting p53 to mitochondria.
It is well established that E1B-19K suppresses apoptosis induced by a multitude of stimuli, some of which activate p53 expression (reviewed in Chinnadurai, 1998) . The various external apoptotic stimuli that have been tested against 19K include certain genotoxic agents that activate p53 expression . 19K also efficiently suppresses apoptosis induced by ectopic overexpression of a ts mutant of p53 (Debbas and White, 1993) (also see Figure 5c and d) and vector mediated overexpression of wt p53 (Figure 6 ). Transfection of E1A in primary rodent cells results in increased accumulation of p53 leading to apoptosis (Rao et al., 1992) . Coexpression of E1B-19K efficiently rescues such cells from apoptosis resulting in immortalization and oncogenic transformation. Thus, E1B-19K can efficiently neutralize the apoptotic activity of p53 under a variety of settings. Thus far, it has been believed that 19K antagonizes p53-mediated apoptotic response emanating from the nucleus. Certain BH3-only effectors such as Puma (Nakano and Vousden, 2001) , Noxa (Oda et al., 2000) and Bik (Mathai et al., 2002) are wellknown transcriptional targets of p53. Since E1B-19K efficiently interacts with different BH3-only proteins (reviewed by Chinnadurai, 1998; Cuconati and White, 2002) , it appears that 19K may suppress the nuclear apoptotic activity of p53 by sequestration of BH3-only apoptosis effectors. In light of our present results, it appears that 19K may also antagonize the transcriptionindependent apoptotic activity of p53. Consistent with this notion, we have observed that apoptosis induced by overexpression of a transcriptionally deficient mutant of p53 can be efficiently suppressed by coexpression of unpublished) .
The mechanism by which mitochondrially localized p53 induces apoptosis is not fully understood. The available data support three different models. The first model suggests that interaction of p53 with mitochondrially localized antiapoptotic proteins such as BCL-xL might trigger apoptosis (Mihara et al., 2003) . The second model suggests that interaction of p53 with the mitochondrial proapoptotic protein BAK might activate the multidomain proapoptotic proteins (Leu et al., 2004) . The third model proposes that p53 might activate the multidomain proapoptotic protein BAX by functioning like a BH3-only member without direct interaction with BAX (Chipuk et al., 2004) . Since E1B-19K is a viral BCL-2 family antiapoptosis protein, it could be envisioned that it would have an evolutionary advantage over cellular homologs for interaction with p53. In Ad infected cells, we have observed interaction of p53 with BAK as well as the viral antiapoptosis protein 19K. In these cells, we have not detected any interaction of p53 with BAX. By dual interaction with p53 and BAK, E1B-19K may prevent BAK activation (oligomerization) as well as BAK-dependent BAX activation (Henry et al., 2002) . Thus, the 19K protein may function at multiple levels to block mitochondrial death signal propagation during p53-mediated apoptosis.
It is generally believed that p53 negatively regulates viral replication through modulation of the G1/S cell cycle checkpoint and induction of apoptosis as a cellular antiviral defense strategy. However, in Ad infected cells there is an increase in the levels of p53 during early stages of infection and p53 is degraded only at late stages of infection. Why should Ad retain a strategy to accumulate p53 during early phases of infection, but target it for degradation at late stages? We have observed that p53 could play a role in lateral viral spread in human epithelial cells. Our results are consistent with the earlier reports in which such a role of p53 in Ad replication cycle has been suggested (Hall et al., 1998; Dix et al., 2000; Koch et al., 2001) . We speculate that the role of p53 in Ad replication might be required to lower the threshold for cell death facilitating efficient cell lysis and viral spread. The ability of E1B-19K to suppress such an activity raises an interesting issue why adenovirus should code for a protein that appears to inhibit its spread. Since Ad genome carries other gene products such as E3 ADP that facilitate efficient cell lysis and viral spread (Tollefson et al., 1996) , it is possible that E1B-19K may be more important for quiescent viral infection in certain cell types such as lymphocytes. Thus, our study has increased our understanding of the role of p53 in Ad life cycle and about the mechanisms by which Ad counters the effect of p53.
Materials and methods
Cells and viruses
The human HCT116 adenocarcinoma cell line and the p53 null (p53 À/À ) derivative cell line (gifts from Bert Vogelstein) were cultured in McCoy's 5A medium supplemented with 10% FBS at 371C in a humidified 5.5% CO 2 atmosphere. Ad2 mutant dl250 defective in coding the E1B-19K protein has been described previously (Subramanian et al., 1984 (Subramanian et al., , 1995b . Ad5 mutants dl309 (phenotypic wt, but deficient for E3-14.7K, 14.5K and 10.4K proteins. E3-6.7K protein is expressed, but altered by deletion of two (18 and 19) internal amino acids; Bett et al., 1995) and various E1B mutant derivatives, dl110 (proficient for E1B-19K, but deficient for E1B-55K , dl111 (deficient for E1B-19K, but proficient for E1B-55K , dl118 (deficient for both E1B proteins ) were gifts from Lee Babiss. The Ad-p53 wt vector, which expresses human p53 under the control of the CMV promoter, was a gift from Frank Graham (Bacchetti and Graham, 1993) . The AdLacZ vector, which expresses the Escherichia coli lacZ gene under CMV promoter, has been described (Subramanian and Chinnadurai, 2003) . The Ad-19KFlag vector expressing E1B-19K protein with C-terminally fused Flag epitope tag (in the E1A-E1B region) was constructed in a similar fashion. Briefly, 3xFlag sequence was amplified by PCR from p3XFLAG-CMV-7.1 expressing vector (Sigma Chemicals, St Louis, MO, USA) and subcloned into the pcDNA-19K vector in frame with 19K. The 19KFlag fragment was then excised and inserted into the shuttle plasmid pLendCMV. The resulting plasmid, pLendCMV19KFlag, was cotransfected with pBHGE3 into 293 cells and plaques were analysed by Western blotting to identify the recombinant viruses expressing E1B-19KFlag. For double infections, the viruses were premixed before infection at a multiplicity (MOI) of 50 PFU/cell of each virus. To determine the effect of p53 on viral spread, HCT116 p53 þ / þ and p53 À/À cells were plated at 5 Â 10 4 cells per 35 mm dish, next day infected with Ad2 wt and dl250 at an MOI of 0.1 PFU/cell. After 144 h virus titers were determined on A549 cells by standard plaque assay.
Cell death assays and statistical analysis
Cells were plated at 5 Â 10 5 cells/dish in 35 mm dishes and infected on the following day with Ad2 wt or dl250 at an MOI of 50 PFU/cell and the effects on cell viability and DNA fragmentation were assayed at different times postinfection as indicated in the figure legend. Infected cells (floating and attached) were harvested by trypsinization, washed twice with PBS, and assayed for cell viability by flow cytometry on a Guava PC personal flow cytometer (Guava Tecnologies). The hazard functions for Ad-infection were estimated on the basis of cell viability (survival) data as the inverse functions to the empirical survival functions (Collett, 2003) . The differences in the hazard curves were assessed using the log-rank test. The t-test was used to compare the differences in mean values. The Microsoft Excel software was used for calculations. The extent of cell death was also assed on the basis of analysis of low molecular weight DNA extracted from infected cells essentially as described (Subramanian et al., 1995b) and was quantified using the ImageQuant software.
Plasmids and transfection
HCT116 p53
þ / þ or p53 À/À cells were plated at 5 Â 10 6 cells per 100 mm diameter dish, and on the next day they were transfected with various p53 expression plasmids (pcDNA3p53 wt, pcDNA3p53R175H, pcDNA3L194F, pcDNA3R273H) (Mihara et al., 2003) (gift from U Moll, Stony Brook University, NY, USA) and various 19K expression plasmids (pcDNA319K, pRcCMV-19K, pRcCMV19KE2A/A3S, pRcCMV19KR14A/N15S and pRcCMV19KW123A/R124S) . The plasmids were transfected by using the FuGene 6 transfection reagent as recommended by the manufacturer (Roche Molecular Biochemicals). At 48 h after transfection cells were harvested and used for protein analysis.
Preparation and analysis of subcellular fractions
HCT116 p53
þ / þ and HCT116 p53 À/À cells were either mockinfected or infected with viruses as indicated in the figure legends. Cells were harvested at indicated times by gentle scrapping with a rubber policemen, collected by centrifugation at 200 g for 5 min at 41C, and washed twice with ice-cold PBS, pH 7.4. Cells were suspended in buffer A (250 mM sucrose, 20 mM HEPES-KOH, pH 7.4, 10 mM KCl, 1.5 mM Na-EGTA, 1.5 mM Na-EDTA, 1 mM MgCl 2 and 1 mM dithiothreitol) and a cocktail of protease inhibitors (Roche) to preserve the mitochondrial integrity, allowed to swell on ice for 30 min. Cells were disrupted by 50 strokes in a glass Dounce homogenizer with a tight-fitting pestle (type B). The cell homogenates were centrifuged at 600 g for 8 min at 41C. Supernatants were further centrifuged at 13 000 g for 15 min to separate the heavy membrane (HM) fraction enriched for mitochondria (pellet 2) and cytosolic fraction (supernatant 2). Pellet 2 was washed twice with buffer A before lysis to ensure the lack of contamination with cytosolic proteins. Pellet 1 containing nuclei and unbroken cells was washed with PBS, resuspended in ice-cold hypotonic buffer B (10 mM HEPES, pH 7.4, 1.5 mM MgCl 2 , 10 mM KCl, 0.5 mM DTT, cocktail of protease inhibitors), incubated in ice for 10 min, dounced with 10 strokes to disrupt unbroken cells, centrifuged for 5 min at 3000 r.p.m. The resulting pellet was washed twice before lysis. To prepare the whole-cell lysate (WCL), cells were harvested, and washed twice with PBS. The cells were lysed for 1 h in icecold buffer containing 50 mM Tris-HCl, pH 8, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, supplemented with protease inhibitor mixture (Roche). The lysates were clarified by centrifugation at 13 000 g for 15 min at 41C. Supernatants were collected, and the amount of soluble protein in each fraction was then quantified by detergentcompatible protein assay (Bio-Rad, Richmond, CA, USA).
Immunoprecipitation
For immunoprecipitation analysis, cells were plated on 100 mm diameter dishes (5 Â 10 6 cells/dish) and were treated as indicated in the figure legends. Cells were lysed in 1 ml of a buffer containing 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 10% glycerol, 1% 3-[(3-cholamidopropyl)-dimethylammonio]-1-propanesulfonate (CHAPS), 2 mM Na-EDTA, and a cocktail of protease inhibitors (Roche) for 1 h on ice. Insoluble cell debris was removed by centrifugation at 13 000 g for 15 min at 41C. The resulting supernatants were cleared by incubation with 50 ml of protein A-Sepharose beads (Sigma Chemicals, St Louis, MO, USA) for 1 h at 41C on a rocking shaker. Protein A beads were removed by centrifugation at 4000 g at 41C for 1 min. The resulting supernatants containing equal amounts of the total protein were mixed with antibodies (indicated in the figure legends) and gently rocked overnight at 41C on a rocking shaker. When primary nonconjugated antibodies were used, the immune complexes were captured by adding 50 ml of protein A-Sepharose beads and gentle rocking for 2 h at 41C. The beads were collected by pulse centrifugation, washed four to five times with ice-cold buffer containing 50 mM Tris-HCl, pH 7.5 and 150 mM NaCl, resuspended in SDS-PAGE sample buffer, mixed and boiled for 3 min to dissociate immune complexes from the beads. The beads were collected by centrifugation, and the resulting supernatants were used for Western blot analysis.
Western blot analysis
Samples containing equal amounts of total protein (25-50 mg) were mixed with Laemmli's loading buffer, boiled for 5 min, and subjected to SDS-PAGE (10 or 15%) followed by electroblotting onto nitrocellulose membrane. Membranes were blocked for 1 h with 5% (wt/vol) nonfat milk in Trisbuffered saline, pH 7.6, containing 0.1% Tween-20 at room temperature and subsequently probed overnight at 41C with various monoclonal and polyclonal antibodies. The membranes were washed and incubated for 30 min with the corresponding secondary antibodies (Santa Cruz). The membranes were then washed, and protein bands were visualized with Western blotting detection reagent (Roche) according to the manufacturer's instructions.
GST pull-down assays
Recombinant GST-19K protein was generated using pGEX-19K vector (Boyd et al., 1994) . The expression of GST or GST-19K was induced for 5 h with 1 mM IPTG in BL21Star(DE3) cells. For purification GST or proteins, the bacterial pellets were lysed in NETN buffer (50 mM Tris, pH 8.0, 100 mM NaCl, 1 mM EDTA, 0.5% NP40), precleared by centrifugation, and applied to glutathione-agarose matrix (Sigma, St Louis, MO, USA) for 15 min at 41C. Agarose beads were then washed five times with NETN buffer and stored at 41C. An aliquot of the beads was resuspended in 2 Â SDS sample buffer, subjected to SDS-PAGE, and stained with Sypro Orange protein gel stain (Molecular Probes, Eugene, OR, USA) to estimate protein concentration using BSA as the standard. GST pull-down assay was performed as described . Briefly, 20 ml of GST-19K or GST beads (containing 1 mg of protein) were incubated with 0.75 mg full-length recombinant human p53 protein (Pharmingen, San Diego, CA, USA) at room temperature for 60 min with agitation in 1% Chaps buffer. After brief centrifugation, the beads were washed five times, resuspended in SDS sample buffer. Samples were subjected to SDS-PAGE and Western blotting to visualize the protein bands.
Antibodies
The following antibodies were used: anti-p53 monoclonal DO-1 antibody (Oncogene, CA, USA) or G59-12 (Pharmingen, San Diego, CA, USA), anti-E1B-19K rabbit antiserum generated against the synthetic peptide H-CQEQSPWNPRAGLDPRE-OH) or rat monoclonal 1G11 antibody (Oncogene, San Diego, CA, USA), anti-E1B-55K monoclonal antibody (gift from Peter Yaciuk), anti-E4-orf6, 6/7 mouse monoclonal antibody (gift from Pat Hearing), the monoclonal anticytochrome oxidase subunit IV antibody (Molecular Probes, Eugene, OR, USA), anti-PCNA rabbit polyclonal (FL-261) antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-BAK NT and anti-BAX NT rabbit polyclonal antibodies (Upstate, Charlottesville, VA, USA).
Colony rescue assay
BRKtsp53 cells (5 Â 10 5 cells per 25 cm 2 flask) were transfected by the standard calcium phosphate coprecipitation method with 10 mg of the vector or 19K expressing plasmids (pRcCMV-19K wt, pRcCMV19KE2A/A3S, pRcCMV19KR 14A/N15S and pRcCMV19KW123A/R124S). At 48 h after transfection, cells were transferred to 32.51C to induce p53-dependent apoptosis and incubated for 48 h. Cells were then shifted back to 38.51C, placed under G418 selection (250 mg/ml) for 14 days, fixed and stained with crystal violet (1% crystal violet, 10% formaldehyde, 20% ethanol). For quantification of the total number of cells, the dye was extracted from each flask with 2 ml of 30% acetic acid and the absorbance of the resulting solution was measured at 560 nm.
